Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAIN SCIENTIFIC INC.BRSF · Entity 124256 | 10% owner | June 15, 2022 | August 04, 2022 |
| Modular Medical, Inc.MODD · Entity 7488 | Chief Executive Officer · 10% owner | April 24, 2025 | April 28, 2025 |
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | 10% owner | January 15, 2021 | January 21, 2021 |
| SANUWAVE Health, Inc.SNWV · Entity 7321 | Director by Deputization | December 11, 2025 | December 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAIN SCIENTIFIC INC.
Report date June 15, 2022 · Filed August 04, 2022
Jointly reported with MANCHESTER MANAGEMENT CO LLC, MANCHESTER MANAGEMENT PR, LLC, Manchester Explorer, L.P., JEB Partners, L.P., FRANK MORGAN C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 19,545,187 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 19,545,187 F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 12,816,831 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,816,831 F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 8,028,706 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,028,706 F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The reported warrants are exercisable as of the issue date, subject to certain conditions. F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions. F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: The reported warrants are exercisable as of the issue date, subject to certain conditions. F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions. F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F4: The reported warrants are exercisable as of the issue date, subject to certain conditions. F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions. F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2031-10-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F6: The reported warrants are subject to a blocker provision that prevents James E. Besser from exercising the warrants if he would be more than a 4.99% beneficial owner of the Common Stock, $0.001 par value, following such exercise. The foregoing description of the warrant does not purport to be complete and is subject to and qualified in its entirety by reference to the Common Stock Purchase Warrant included as Exhibit 4.1 of the Issuer's 8-K filed on October 7, 2021, which is incorporated by reference. F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity.
F4: The reported warrants are exercisable as of the issue date, subject to certain conditions.
F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions.
F6: The reported warrants are subject to a blocker provision that prevents James E. Besser from exercising the warrants if he would be more than a 4.99% beneficial owner of the Common Stock, $0.001 par value, following such exercise. The foregoing description of the warrant does not purport to be complete and is subject to and qualified in its entirety by reference to the Common Stock Purchase Warrant included as Exhibit 4.1 of the Issuer's 8-K filed on October 7, 2021, which is incorporated by reference.
Modular Medical, Inc.
Report date April 24, 2025 · Filed April 28, 2025
Jointly reported with MANCHESTER MANAGEMENT CO LLC, MANCHESTER MANAGEMENT PR, LLC, FRANK MORGAN C., Manchester Explorer, L.P., JEB Partners, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2035-04-24 | Direct | 125,000 |
Reported balance
After 2025-04-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-24 · Grant · Acquired 125,000 · Balance 125,000 F1: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026. F2: The reported securities are directly owned by James E. Besser in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2035-03-31 | Direct | 1,875 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,875 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2035-03-31 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2034-12-31 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-06-30 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2034-03-31 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2033-12-29 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2033-10-02 | Direct | 135,136 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 135,136 F8: This option has vested since (i) all verification and validation testing for the Registrant's initial pump product was completed by December 31, 2023 and (ii) the 510(K) premarket submission to the U.S. Food and Drug Administration ("FDA") for the Registrant's initial pump product was completed by January 31, 2024. F2: The reported securities are directly owned by James E. Besser in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2033-09-30 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2033-06-30 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2033-03-31 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2032-12-31 | Direct | 1,875 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 1,875 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2032-12-31 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 7,500 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2032-09-30 | Direct | 1,875 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 1,875 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2032-09-30 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 7,500 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2032-06-30 | Direct | 3,634 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 3,634 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2032-07-19 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 7,500 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-03-31 | Direct | 4,486 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 4,486 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-03-31 | Direct | 17,943 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 17,943 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2031-12-31 | Direct | 9,987 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · Balance 9,987 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2031-12-31 | Direct | 2,497 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · Balance 2,497 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2031-09-30 | Direct | 8,389 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · Balance 8,389 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2031-09-30 | Direct | 2,097 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · Balance 2,097 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2031-06-30 | Direct | 5,297 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · Balance 5,297 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2030-05-12 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · Balance 50,000 F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2029-03-25 | IndirectSee footnote | 260,416 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 260,416 F5: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2027-02-14 | IndirectSee footnote | 234,274 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 234,274 F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2027-02-10 | IndirectSee footnote | 300,000 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · Balance 300,000 F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $8.61 · Expires 2027-02-06 | IndirectSee footnote | 119,237 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · Balance 119,237 F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2029-03-25 | Direct | 78,125 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 78,125 F7: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F2: The reported securities are directly owned by James E. Besser in his personal capacity. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026.
F2: The reported securities are directly owned by James E. Besser in his personal capacity.
F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.
F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity.
F5: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.
F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F7: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.
F8: This option has vested since (i) all verification and validation testing for the Registrant's initial pump product was completed by December 31, 2023 and (ii) the 510(K) premarket submission to the U.S. Food and Drug Administration ("FDA") for the Registrant's initial pump product was completed by January 31, 2024.
F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date January 15, 2021 · Filed January 21, 2021
Jointly reported with FRANK MORGAN C., MANCHESTER MANAGEMENT CO LLC, MANCHESTER MANAGEMENT PR, LLC, Manchester Explorer, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 492,951 |
Reported balance
Holding disclosure · report date 2021-01-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 492,951 |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,750,000 |
Reported balance
Holding disclosure · report date 2021-01-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,750,000 F1: The reported securities and warrants are directly owned by Manchester Explorer, L.P. JEB Partners, L.P and by Morgan C. Frank in his personal capacity. The reported securities and warrants are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P. The reported securities and warrants may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester Management Company, LLC. F2: The Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2026-01-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-01-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2026-01-15 | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2021-01-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The reported securities and warrants are directly owned by Manchester Explorer, L.P. JEB Partners, L.P and by Morgan C. Frank in his personal capacity. The reported securities and warrants are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P. The reported securities and warrants may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester Management Company, LLC. F2: The Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities and warrants are directly owned by Manchester Explorer, L.P. JEB Partners, L.P and by Morgan C. Frank in his personal capacity. The reported securities and warrants are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P. The reported securities and warrants may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester Management Company, LLC.
F2: The Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
SANUWAVE Health, Inc.
Report date December 11, 2025 · Filed December 15, 2025
Jointly reported with MANCHESTER MANAGEMENT CO LLC, Manchester Explorer, L.P., FRANK MORGAN C., MANCHESTER MANAGEMENT PR, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectSee Footnote | 70,499 |
Reported balance
After 2025-12-11 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-12-11 · Sale · Disposed 13,500 · Balance 70,499 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $31.05 to $31.525. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Manchester Explorer, L.P. ("Explorer"), (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectSee Footnote | 63,999 |
Reported balance
After 2025-12-12 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-12-12 · Sale · Disposed 6,500 · Balance 63,999 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.765 to $31.60. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Manchester Explorer, L.P. ("Explorer"), (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectSee Footnote | 863,980 |
Reported balance
Holding disclosure · report date 2025-12-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 863,980 F5: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of Explorer, (ii) Manchester PR, the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 2,000 |
Reported balance
Holding disclosure · report date 2025-12-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,000 F4: The reported securities are directly owned by James E. Besser in his personal capacity. |
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 52,653 |
Reported balance
Holding disclosure · report date 2025-12-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 52,653 F6: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Manchester Explorer, L.P. ("Explorer"), (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $31.05 to $31.525. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.765 to $31.60. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The reported securities are directly owned by James E. Besser in his personal capacity.
F5: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of Explorer, (ii) Manchester PR, the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F6: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
FENNEC PHARMACEUTICALS INC.
Report date January 27, 2016 · Filed March 29, 2018
Jointly reported with MANCHESTER MANAGEMENT PR, LLC, MANCHESTER MANAGEMENT CO LLC, Manchester Explorer, L.P., FRANK MORGAN C.
Section 16 reporting ended · disclosed 2018-03-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,666,666 |
Last balance in matching sequence
After 2018-03-28 transaction · row 24
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
15 source rowsRow 1 · 2018-03-08 · Sale · Disposed 10,000 · Balance 2,146,797 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2018-03-12 · Sale · Disposed 18,560 · Balance 2,128,237 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 3 · 2018-03-13 · Sale · Disposed 16,934 · Balance 2,111,303 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 4 · 2018-03-14 · Sale · Disposed 13,600 · Balance 2,097,703 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 5 · 2018-03-16 · Sale · Disposed 6,423 · Balance 2,091,280 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 6 · 2018-03-16 · Sale · Disposed 2,120 · Balance 2,089,160 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 8 · 2018-03-19 · Sale · Disposed 200 · Balance 2,088,960 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 10 · 2018-03-20 · Sale · Disposed 4,200 · Balance 2,084,760 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 12 · 2018-03-20 · Sale · Disposed 15,183 · Balance 2,069,577 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 14 · 2018-03-21 · Sale · Disposed 210,311 · Balance 1,859,266 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 16 · 2018-03-22 · Sale · Disposed 20,000 · Balance 1,839,266 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 18 · 2018-03-23 · Sale · Disposed 3,500 · Balance 1,835,766 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 20 · 2018-03-27 · Sale · Disposed 22,707 · Balance 1,813,059 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 22 · 2018-03-28 · Sale · Disposed 605 · Balance 1,812,454 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 24 · 2018-03-28 · Sale · Disposed 145,788 · Balance 1,666,666 F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 1,250,000 |
Last balance in matching sequence
After 2018-03-28 transaction · row 25
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
10 source rowsRow 7 · 2018-03-16 · Sale · Disposed 2,120 · Balance 1,672,494 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 9 · 2018-03-19 · Sale · Disposed 200 · Balance 1,672,294 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 11 · 2018-03-20 · Sale · Disposed 4,200 · Balance 1,668,094 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 13 · 2018-03-20 · Sale · Disposed 15,183 · Balance 1,652,911 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 15 · 2018-03-21 · Sale · Disposed 210,311 · Balance 1,442,600 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 17 · 2018-03-22 · Sale · Disposed 20,000 · Balance 1,422,600 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 19 · 2018-03-23 · Sale · Disposed 3,500 · Balance 1,419,100 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 21 · 2018-03-27 · Sale · Disposed 22,707 · Balance 1,396,393 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 23 · 2018-03-28 · Sale · Disposed 605 · Balance 1,395,788 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. Row 25 · 2018-03-28 · Sale · Disposed 145,788 · Balance 1,250,000 F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. |
Filing footnotes · ownership attribution and instrument terms
F1: Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions, including Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC as a result of it having investment discretion over certain advisory accounts it manages and by Manchester Management Company, LLC as a result of it being the general partner over certain advisory accounts. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and as a Managing Member of Manchester Management Company, LLC, and by Morgan C. Frank, who serves as a portfolio manager and a consultant of Manchester Management Company, LLC.
F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.
FiEE, Inc.
Report date August 03, 2020 · Filed August 05, 2020
Jointly reported with MANCHESTER MANAGEMENT CO LLC, Manchester Explorer, L.P., FRANK MORGAN C.
Section 16 reporting ended · disclosed 2020-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-08-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-08-03 · Sale · Disposed 4,287,214 · Balance 0 F1: Manchester Management Company, LLC, a Delaware limited liability company ("Manchester"), is principally engaged in the business of providing investment management services. The reported securities are indirectly beneficially owned by Manchester as a result of it having investment discretion over certain advisory accounts it manages, including Manchester Explorer, L.P. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as a Managing Member of Manchester, and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester. Each of the Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-08-03 · Sale · Disposed 2,857,643 · Balance 0 F2: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-03 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-08-03 · Sale · Disposed 143,357 · Balance 0 F3: The reported securities are directly owned by James E. Besser in his personal capacity. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-03 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-08-03 · Sale · Disposed 142,857 · Balance 0 F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
Filing footnotes · ownership attribution and instrument terms
F1: Manchester Management Company, LLC, a Delaware limited liability company ("Manchester"), is principally engaged in the business of providing investment management services. The reported securities are indirectly beneficially owned by Manchester as a result of it having investment discretion over certain advisory accounts it manages, including Manchester Explorer, L.P. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as a Managing Member of Manchester, and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester. Each of the Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2: The reported securities are directly owned by Manchester Explorer, L.P., a Delaware limited partnership.
F3: The reported securities are directly owned by James E. Besser in his personal capacity.
F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity.
Medifirst Solutions, Inc.
Report date May 01, 2019 · Filed May 02, 2019
Section 16 reporting ended · disclosed 2019-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 696,612 |
Reported balance
After 2019-05-01 transaction · row 1
1 source rowRow 1 · 2019-05-01 · Purchase · Acquired 96,612 · Balance 696,612 |
Processa Pharmaceuticals, Inc.
Report date April 06, 2021 · Filed May 05, 2021 · Amendment
Section 16 reporting ended · disclosed 2021-05-05. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectSee footnotes | 648,300 |
Last balance in matching sequence
After 2021-04-08 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-04-06 · Sale · Disposed 31,771 · Balance 1,064,300 F1: These securities are directly owned by Manchester Explorer, L.P. and JEB Partners, L.P. These securities are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P.; these securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC. F2: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2021-04-07 · Sale · Disposed 16,000 · Balance 1,048,300 F1: These securities are directly owned by Manchester Explorer, L.P. and JEB Partners, L.P. These securities are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P.; these securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC. F2: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 3 · 2021-04-08 · Sale · Disposed 400,000 · Balance 648,300 F1: These securities are directly owned by Manchester Explorer, L.P. and JEB Partners, L.P. These securities are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P.; these securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC. F2: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 405,000 |
Reported balance
Holding disclosure · report date 2021-04-06 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 405,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are directly owned by Manchester Explorer, L.P. and JEB Partners, L.P. These securities are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P.; these securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC.
F2: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
SideChannel, Inc.
Report date September 30, 2019 · Filed October 03, 2019
Jointly reported with MANCHESTER MANAGEMENT PR, LLC, MANCHESTER MANAGEMENT CO LLC, Manchester Explorer, L.P.
Section 16 reporting ended · disclosed 2019-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee footnote | 4,261,000 |
Reported balance
After 2019-09-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-09-30 · Purchase · Acquired 10,600 · Balance 4,261,000 F1: The reported securities are directly owned by Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over certain advisory accounts they manage. Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC. F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are directly owned by Manchester Explorer, L.P. The reported securities are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over certain advisory accounts they manage. Manchester Management PR, LLC, a Puerto Rico limited liability company, provides investment management services to private individuals and institutions. The reported securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC.
F2: Each of the Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2025 Filed Dec 15, 2025 22:22 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 6,500 | $21.04 | $136,788.60 |
DisclosureSEC source: 0000919574-25-007394 · ownership.xml · nonDerivative · entry 2 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 63,999 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.765 to $31.60. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Manchester Explorer, L.P. ("Explorer"), (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 22:22 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 13,500 | $31.28 | $422,277.30 |
DisclosureSEC source: 0000919574-25-007394 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 70,499 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $31.05 to $31.525. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Manchester Explorer, L.P. ("Explorer"), (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 02:21 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 8,625 | $30.39 | $262,129.28 |
DisclosureSEC source: 0000919574-25-007315 · ownership.xml · nonDerivative · entry 3 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 863,980 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $30.01 to $30.90. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 20:08 UTC Amendment | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 8,625 | $30.39 | $262,129.28 |
DisclosureSEC source: 0000919574-25-007331 · ownership.xml · nonDerivative · entry 3 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 863,980 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.01 to $30.90. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 02:21 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 8,785 | $30.58 | $268,678.68 |
DisclosureSEC source: 0000919574-25-007315 · ownership.xml · nonDerivative · entry 2 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 872,605 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $30.00 to $31.71. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 20:08 UTC Amendment | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 8,785 | $30.58 | $268,678.68 |
DisclosureSEC source: 0000919574-25-007331 · ownership.xml · nonDerivative · entry 2 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 872,605 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.00 to $31.71. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:21 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 2,000 | $31.60 | $63,203.40 |
DisclosureSEC source: 0000919574-25-007315 · ownership.xml · nonDerivative · entry 4 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F5 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $29.88 to $33.50. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:21 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 125,400 | $30.75 | $3,856,050.00 |
DisclosureSEC source: 0000919574-25-007315 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 881,390 F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 20:08 UTC Amendment | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 2,000 | $31.60 | $63,203.40 |
DisclosureSEC source: 0000919574-25-007331 · ownership.xml · nonDerivative · entry 4 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $29.88 to $33.50. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 20:08 UTC Amendment | SANUWAVE Health, Inc. SNWV · Entity 7321 | SaleCommon Stock, par value $0.001 | 125,400 | $30.75 | $3,856,050.00 |
DisclosureSEC source: 0000919574-25-007331 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 881,390 F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 24, 2025 Filed Apr 28, 2025 16:39 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantOption to purchase common stock · Derivative | 125,000 | $0.94 Strike: $0.94 | $117,500.00 |
DisclosureSEC source: 0000919574-25-002637 · ownership.xml · derivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock, par value $0.001 per share · 125,000 shares Expires 2035-04-24 F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026. F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026. F2 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:34 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock Purchase Warrant · Derivative | 78,125 | $1.12 Strike: $1.12 | $87,500.00 |
DisclosureSEC source: 0000919574-25-002089 · ownership.xml · derivative · entry 6 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,125 Underlying: Common Stock, par value $0.001 per share · 78,125 shares Expires 2029-03-25 F3 · price: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F3 · derivative.exercise_date: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:34 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock Purchase Warrant · Derivative | 260,416 | $1.12 Strike: $1.12 | $291,665.92 |
DisclosureSEC source: 0000919574-25-002089 · ownership.xml · derivative · entry 5 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 260,416 Underlying: Common Stock, par value $0.001 per share · 260,416 shares Expires 2029-03-25 F1 · price: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F1 · derivative.exercise_date: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F2 · ownership.nature: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:34 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 156,250 | $1.92 | $300,000.00 |
DisclosureSEC source: 0000919574-25-002089 · ownership.xml · nonDerivative · entry 2 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,000 F3 · price: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:34 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 520,832 | $1.92 | $999,997.44 |
DisclosureSEC source: 0000919574-25-002089 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,805,575 F1 · price: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F2 · ownership.nature: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 18:05 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 21,000 | $1.68 | $35,235.90 |
DisclosureSEC source: 0000919574-24-007009 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner Manchester Explorer, L.P. · CIK 0001411524 · 10% owner · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.65 to $1.73. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| November 27, 2024 Filed Nov 29, 2024 10:00 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 100,000 | $1.69 | $168,950.00 |
DisclosureSEC source: 0000919574-24-006936 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner Manchester Explorer, L.P. · CIK 0001411524 · 10% owner · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,750 F1 · price: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.direct: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 19:46 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 166,666 | $1.50 | $249,999.00 |
DisclosureSEC source: 0000919574-24-006890 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,284,743 F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 14,167 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 36 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 14,167 shares Expires 2027-08-05 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F9 · ownership.direct: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 15,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 35 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 15,000 shares Expires 2027-08-05 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F9 · ownership.direct: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 22,667 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 34 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 22,667 shares Expires 2027-11-15 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F8 · ownership.direct: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F8 · ownership.nature: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 24,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 33 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 24,000 shares Expires 2027-11-15 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F8 · ownership.direct: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F8 · ownership.nature: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 6,375 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 32 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 6,375 shares Expires 2024-01-21 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 42,498 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 31 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 42,498 shares Expires 2024-01-21 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 6,750 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 30 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 6,750 shares Expires 2024-01-21 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 44,998 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 29 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 44,998 shares Expires 2024-01-21 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionFuture Advance Convertible Promissory Note · Derivative | 8,625 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 28 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 8,625 shares Expires 2025-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F6 · derivative.exercise_price: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · derivative.underlying_shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionFuture Advance Convertible Promissory Note · Derivative | 57,498 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 27 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 57,498 shares Expires 2025-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F6 · derivative.exercise_price: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · derivative.underlying_shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 5,667 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 26 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 5,667 shares Expires 2028-12-30 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 6,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 25 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 6,000 shares Expires 2028-12-30 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionFuture Advance Convertible Promissory Note · Derivative | 7,667 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 24 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 7,667 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F6 · derivative.exercise_price: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · derivative.underlying_shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 17,000 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 23 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 17,000 shares Expires 2028-05-10 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 18,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 22 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 18,000 shares Expires 2028-05-10 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 141,667 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 21 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 141,667 shares Expires 2027-08-05 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock Purchase Warrant · Derivative | 150,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · derivative · entry 20 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 150,000 shares Expires 2027-08-05 F1 · derivative.exercise_price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.exercise_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.exercise_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F1 · derivative.expiration_date: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · derivative.expiration_date: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · derivative.underlying_shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · derivative.underlying_shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F7 · ownership.direct: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 14,167 | $25.13 | $356,016.71 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 18 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,653 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F5 · price: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F9 · ownership.direct: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 15,000 | $15.00 | $225,000.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 17 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,486 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F4 · price: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F9 · ownership.direct: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 22,667 | $25.13 | $569,621.71 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 16 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 83,999 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F5 · price: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F8 · ownership.nature: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 24,000 | $15.00 | $360,000.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 15 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 61,332 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F4 · price: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F8 · ownership.nature: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | PurchaseCommon Stock, par value $0.001 | 181,818 | $8.25 | $1,499,998.50 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 14 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,006,790 F11 · kind: On October 16, 2024, Explorer entered into a securities purchase agreement (the "Purchase Agreement") with the Issuer, pursuant to which Explorer acquired 181,818 shares of the Issuer's Common Stock from the Issuer in a private placement at a price of $8.25 per share of Common Stock (the "Private Placement"), in each case, after adjustment to reflect the Reverse Stock Split. The Private Placement closed on October 18, 2024. The foregoing descriptions of the Purchase Agreement and the Private Placement do not purport to be complete and is subject to and qualified in its entirety by reference to the 8-K, which is incorporated herein by reference. F11 · shares: On October 16, 2024, Explorer entered into a securities purchase agreement (the "Purchase Agreement") with the Issuer, pursuant to which Explorer acquired 181,818 shares of the Issuer's Common Stock from the Issuer in a private placement at a price of $8.25 per share of Common Stock (the "Private Placement"), in each case, after adjustment to reflect the Reverse Stock Split. The Private Placement closed on October 18, 2024. The foregoing descriptions of the Purchase Agreement and the Private Placement do not purport to be complete and is subject to and qualified in its entirety by reference to the 8-K, which is incorporated herein by reference. F11 · price: On October 16, 2024, Explorer entered into a securities purchase agreement (the "Purchase Agreement") with the Issuer, pursuant to which Explorer acquired 181,818 shares of the Issuer's Common Stock from the Issuer in a private placement at a price of $8.25 per share of Common Stock (the "Private Placement"), in each case, after adjustment to reflect the Reverse Stock Split. The Private Placement closed on October 18, 2024. The foregoing descriptions of the Purchase Agreement and the Private Placement do not purport to be complete and is subject to and qualified in its entirety by reference to the 8-K, which is incorporated herein by reference. F11 · balance_after: On October 16, 2024, Explorer entered into a securities purchase agreement (the "Purchase Agreement") with the Issuer, pursuant to which Explorer acquired 181,818 shares of the Issuer's Common Stock from the Issuer in a private placement at a price of $8.25 per share of Common Stock (the "Private Placement"), in each case, after adjustment to reflect the Reverse Stock Split. The Private Placement closed on October 18, 2024. The foregoing descriptions of the Purchase Agreement and the Private Placement do not purport to be complete and is subject to and qualified in its entirety by reference to the 8-K, which is incorporated herein by reference. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 6,375 | $25.13 | $160,203.75 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 13 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 824,971 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F5 · price: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 42,498 | $25.13 | $1,067,974.74 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 12 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 818,596 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F5 · price: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 6,750 | $15.00 | $101,250.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 11 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 776,098 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F4 · price: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 44,998 | $15.00 | $674,970.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 10 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 769,348 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F4 · price: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionCommon Stock, par value $0.001 | 8,625 | $15.00 | $129,375.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 9 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 724,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F6 · price: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · balance_after: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionCommon Stock, par value $0.001 | 57,498 | $15.00 | $862,470.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 8 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 715,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F6 · price: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · balance_after: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 5,667 | $25.13 | $142,411.71 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 7 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 658,227 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F5 · price: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 6,000 | $15.00 | $90,000.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 6 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 652,560 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F4 · shares: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F4 · price: Pursuant to the terms of the Exchange, the $15.00 Warrants were each exchanged for approximately 0.0024 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionCommon Stock, par value $0.001 | 7,667 | $15.00 | $115,005.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 5 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 646,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · shares: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F6 · price: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F6 · balance_after: Pursuant to the terms of the Exchange, each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 17:03 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | OtherCommon Stock, par value $0.001 | 17,000 | $25.13 | $427,210.00 |
DisclosureSEC source: 0000919574-24-005981 · ownership.xml · nonDerivative · entry 4 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director by Deputization Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 638,893 F1 · kind: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · kind: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F3 · shares: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F5 · shares: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F1 · price: On October 18, 2024, effective upon the implementation of the Reverse Stock Split (as defined below), the Company issued an aggregate of 3,989,456 shares of Common Stock in exchange for all outstanding (A) Future Advance Convertible Promissory Notes ("Notes") and (B) Common Stock Purchase Warrants issued by the Company in private placements in August 2022, November 2022, May 2023, December 2023, January 2024 and June 2024 (collectively, the "Warrants") ((A) and (B), together, the "Exchange"). Pursuant to the Exchange, after adjustment to reflect the Reverse Stock Split, (i) each outstanding Note was fully accelerated to maturity (with 15% interest paid on the outstanding principal) and then converted (per the terms of the Note) into shares of Common Stock at $15.00 per share, (ii) each Warrant with an exercise price of $15.00 per share (i.e., $0.04 prior to the Reverse Stock Split) was exchanged for 0.0024 shares of F2 · price: (cont'd from footnote 1) Common Stock per share subject to such Warrant (the "$15.00 Warrants"), and (iii) each Warrant with an exercise price of $25.13 per share (i.e., $0.067 prior to the Reverse Stock Split) was exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant (the "$25.13 Warrants"). Simultaneous with the Exchange, each Warrant was exchanged pursuant to the mechanics reported by the Reporting Persons on the other Form 4 filed on October 22, 2024 by the Reporting Persons, which is incorporated herein by reference. The foregoing transactions, including the Exchange, were approved by the Board of Directors of the Issuer. The foregoing description of the Exchange does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's 8-K filed on October 18, 2024 (the "8-K"), which is incorporated herein by reference. F5 · price: Pursuant to the terms of the Exchange, the $25.13 Warrants were each exchanged for approximately 0.0023 shares of Common Stock per share subject to such Warrant. F3 · balance_after: On October 15, 2024, the Issuer filed a Certificate of Amendment to its Articles of Incorporation, as amended (the "Certificate of Amendment"), to implement a 1-for-375 reverse stock split (the "Reverse Stock Split") of Common Stock. As a result of the Reverse Stock Split, at 12:01 a.m. Mountain Time on October 18, 2024, every 375 shares of Common Stock then issued and outstanding automatically were combined into one share of Common Stock, with no change in par value per share. No fractional shares were outstanding following the Reverse Stock Split, and any fractional shares that would have resulted from the Reverse Stock Split will be settled in cash. The text of the Certificate of Amendment that effected the foregoing actions was included as Exhibit 3.1 of the 8-K and is incorporated herein by reference. As a result of the foregoing, the number of reported securities herein is on a post-Reverse Stock Split basis. F7 · ownership.nature: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.